<DOC>
	<DOCNO>NCT00022620</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness paclitaxel treat patient refractory recurrent endometrial cancer .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With Refractory Recurrent Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine therapeutic activity paclitaxel patient refractory recurrent endometrial papillary carcinoma . - Determine objective response duration response patient treat regimen . - Determine acute side effect regimen patient . OUTLINE : This multicenter study . Patients receive paclitaxel IV 3 hour day 1 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Patients follow every 12 week . PROJECTED ACCRUAL : Approximately 16-29 patient accrue study .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm endometrial papillary carcinoma ( uterine papillary serous carcinoma ) Progressive recurrent Bidimensionally measurable disease Platinum refractory disease , define one following : Progression platinumbased chemotherapy Stable disease least 4 course platinumbased chemotherapy Recurrence within 4 month platinumbased chemotherapy No brain involvement leptomeningeal disease PATIENT CHARACTERISTICS : Age : 75 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 50 umol/L Renal : BUN great 8.0 mmol/L Creatinine great 120 umol/L Creatinine clearance least 60 mL/min Other : Not pregnant Fertile patient must use effective contraception HIV negative No prior concurrent malignancy except basal cell carcinoma skin No active bacterial infection ( e.g. , urinary tract infection ) No uncontrolled potentially active site infection ( e.g. , fistula abscess ) No psychological , familial , sociological , geographical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy At least 1 prior platinum contain regimen At least 50 mg/m2 per course maximum 28 day cisplatin At least 5 time AUC maximum 4 week per course carboplatin Prior nontaxanecontaining chemotherapy allow Endocrine therapy : At least 4 week since prior hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy At least 3 month since prior radiotherapy target lesion Concurrent radiotherapy allow bone pain provide evaluable lesion outside irradiation field ) Surgery : Prior surgical management lymph node allow</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>endometrial papillary serous carcinoma</keyword>
</DOC>